Fosaprepitant for the Prevention of Nausea and Vomiting in Patients Receiving BEAM or High-Dose Melphalan Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation  by Clark, Stephen M. et al.
Table 1
Results Fosaprepitant vs. Control, Overall Assessment Period
Control
(n¼70)
FOS
(n¼43)
No emesis (%) 65.7 81.4
Abstracts / Biol Blood Marrow Transplant 20 (2014) S286eS296 S287not statistically signiﬁcant, our results did show a trend in
decreased LOS, readmission at 30 days, and use of antimi-
crobials. Use of IV IST were signiﬁcantly decreased. Incor-
poration of clinical pharma should be strongly considered in
this pt population.Day(s) of melphalan (%) 98 99
Days 1-5 post-melphalan (%) 66 84
Complete response (%)
(no emesis or breakthrough antiemetic use)
1.4 4.7
Emetic episode per patient (mean) 0.76 0.28
Breakthrough antiemetic doses per patient (mean) 9.6 9.98
Complete protection (%)
(no emesis, breakthrough antiemetics,
or signiﬁcant nausea)
- 9.7*
No nausea (%)
(<5 mm on 100 mm VAS)
- 16.1*
No signiﬁcant nausea (%)
(<25 mm on 100 mm VAS)
- 35.5*
*For 31 evaluable subjects446
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Graft-versus-host-disease (GVHD) is a life threatening
complication of allogeneic hematopoietic stem cell trans-
plantation (HSCT). The calcineurin inhibitor tacrolimus is
commonly used in combination with other immunosup-
pressants to prevent GVHD; however the optimal serum
target concentration for tacrolimus in this population re-
mains unknown. A retrospective review was conducted to
determine whether an association exists between tacrolimus
concentrations and transplant-related outcomes, speciﬁcally
acute GVHD, as well as the rate of renal toxicity and mor-
tality. Data from 203 patients who underwent an allogeneic
HSCT from a related (n¼95) or unrelated (n¼108) donor
between January 1, 2003 and December 31, 2011 at a large
academic hospital was analyzed. Sixty-two (31%) patients
developed acute GVHD within the ﬁrst 30 days following
allogeneic stem cell transplant. Median tacrolimus concen-
trations at day 0, 7, 14, and 28 were 11.2, 13.8, 13.5 and 10.2
ng/mL, respectively among those who developed acute
GVHD. Patients who did not develop acute GVHD had similar
tacrolimus concentrations of 10.4,13.1,12.3 and 9.9 ng/mL for
the same respective time points. Serum tacrolimus concen-
trationswere similar across all grades of GVHD and therewas
no correlation between drug concentrations with respect to
renal toxicity. Patients who developed renal dysfunction
(n¼18) had tacrolimus concentrations similar to the median
concentration of the entire cohort, including those who did
not experience renal toxicity. Overall mortality among the
203 included patients was 49%. Mortality was higher among
patients who developed acute GVHD (55%) than in patients
who did not experience the disease (47%). The results of this
analysis support previous conclusions that tacrolimus blood
concentrations are not associated with acute GVHD within
the ﬁrst 30 days post allogeneic HSCT.447
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Chemotherapy-induced nausea and vomiting (CINV) occurs
frequently during hematopoietic stem cell transplantation
(HSCT) despite prophylactic therapy with serotonin antago-
nists and corticosteroids. Aprepitant, an oral neurokinin-1
(NK1) inhibitor, has been considered as add-on prophylactic
therapy; however, to date no published studies have inves-
tigated the injectable NK1 inhibitor fosaprepitant (FOS) in
HSCT. The purpose of this study is to assess the ability of FOSto reduce emesis after BEAM and high-dose melphalan
autologous HSCT.
The use of a 150 mg fosaprepitant IV x 1 prior to melphalan
became standard practice at our institution in the summer of
2012 for BEAM and high-dose melphalan regimens. We
performed an IRB approved cohort study comparing patients
who prospectively receive FOS to a historical cohort who did
not receive FOS. The primary endpoint was overall percent-
age of patients with no emesis during the assessment period
(ﬁrst day of melphalan through ﬁve days after melphalan
administration). Secondary endpoints include number of
emetic episodes per patient, number of breakthrough anti-
emetic doses per patient, and complete response rate (no
emesis or breakthrough antiemetic use). Patients in the FOS
cohort also recorded nausea on a 100 mm visual analog scale
(VAS) daily allowing for additional exploratory endpoints of
complete protection rate (complete response plus no sig-
niﬁcant nausea), no signiﬁcant nausea (< 25 mm on 100 mm
VAS), and no nausea (< 5mmon 100mmVAS) to be assessed
for that single cohort. A sample size of 70 patients per cohort
was deemed necessary based on an estimated 40% no emesis
in control group for 80% power at alpha¼0.05 to detect a 25%
absolute increase in patients with no emesis.
Seventy consecutive patients who received BEAM or high-
dose melphalan without FOS were included in the historical
cohort and 43 patients have received FOS in the prospective
cohort. Interim results suggest the addition of FOS improved
the percentage of patients with no emesis and the number of
emetic episodes per patient. Exploratory endpoints in the
FOS cohort which included patient reported nausea assess-
ments on a VAS are encouraging as a third of patients re-
ported no signiﬁcant nausea during the overall assessment
period. Based on these promising interim results, enrollment
in the FOS cohort is ongoing.448
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Anti-thymocyte globulin (ATG) during conditioning for
allogeneic HSCT is often accompanied by infusion reactions;
